Overview

Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive

Status:
Withdrawn

Trial end date:
2020-06-25

Target enrollment:

Participant gender:

Summary

This is a prospective, controlled, randomized, open label study, aimed at comparing FVIII/VWF concentrates with FVIII concentrates at 200 IU/kg daily in their ability to induce immune tolerance in Haemophilia A patients with high responding inhibitors and poor prognosis for success.

Phase:

N/A

Details

Lead Sponsor:

City of Hope Medical Center

Collaborators:

Biotest Pharmaceuticals Corporation
Charta Fondazione
Charta Foundation
CSL Behring
Grifols Biologicals Inc.
Grifols Biologicals, LLC
Grifols Therapeutics Inc.
Grifols Therapeutics LLC

Treatments:

Factor VIII